| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1999;100:1528-1532.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
Generation of Anti-Hirudin Antibodies in Heparin-Induced Thrombocytopenic Patients Treated With R-Hirudin
From the First Department of Medicine, Faculty of Clinical Medicine Mannheim, University of Heidelberg.
Correspondence to Job Harenberg, MD, Professor of Medicine, First Department of Medicine, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer, 68167 Mannheim, Germany. E-mail J-Harenberg{at}t-online.de
Background—Hirudin is a small
protein with strong thrombin inhibition that may be antigenic. The
generation and disappearance of anti-hirudin antibodies were
investigated in patients with heparin-induced thrombocytopenia who were
treated with recombinant hirudin (r-hirudin) for 
5 days.
Methods and Results—The IgA, IgE, IgG, and IgM isotypes of
anti-hirudin antibodies were determined by ELISA before and after the
start of r-hirudin therapy. A total of 56% of patients (13 of 23)
developed 1 antibody isotype during therapy. No IgE antibodies were
generated. IgA, IgG, and IgM antibodies were detected in 30% (7 of
23), 52% (12 of 23), and 17% (4 of 23) of patients, respectively.
Four patients generated only IgG, 2 patients developed either IgM or
IgG and IgM, 5 patients IgG and IgA, and 2 patients IgG, IgM, and IgA
antibodies. IgM antibodies disappeared within 8 days of the cessation
of r-hirudin. IgA and IgG antibodies disappeared within 1 year in all
but 1 patient. Binding of purified IgG to r-hirudin in IgG
antibody–positive patients (n=7) was demonstrated by competitive ELISA
for r-hirudin. Of the 7 IgG antibody samples, 1 each neutralized or
enhanced the anticoagulant activity of r-hirudin.
Conclusions—R-hirudin may be antigenic in patients with heparin-induced thrombocytopenia. More comprehensive investigations will be required to determine the biological relevance of this and to establish the antibody-generation pattern in other diseases.
Key Words: antibodies • anticoagulants • proteins • thrombosis
This article has been cited by other articles:
 |
|
 |
|
  J. H. Levy, K. A. Tanaka, and M. J. Hursting Reducing Thrombotic Complications in the Perioperative Setting: An Update on Heparin-Induced Thrombocytopenia Anesth. Analg., September 1, 2007; 105(3): 570 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sanmartin, R. F. Bonvini, V. Verin, M. Righini, G. W. Stone, M. Hamon, and H. White Bivalirudin in Acute Coronary Syndromes N. Engl. J. Med., March 8, 2007; 356(10): 1069 - 1071. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kodityal, P. H. Nguyen, A. Kodityal, J. Sherer, M. J. Hursting, and L. Rice Argatroban for Suspected Heparin-Induced Thrombocytopenia: Contemporary Experience at a Large Teaching Hospital J Intensive Care Med, March 1, 2006; 21(2): 86 - 92. [Abstract] [PDF]
|
|
|
|
 |
|
 I.-K. Jang and M. J. Hursting When Heparins Promote Thrombosis: Review of Heparin-Induced Thrombocytopenia Circulation, May 24, 2005; 111(20): 2671 - 2683. [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Gurbuz, W. G. Elliott, and A. A. Zia Heparin-induced thrombocytopenia in the cardiovascular patient: diagnostic and treatment guidelines Eur. J. Cardiothorac. Surg., January 1, 2005; 27(1): 138 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Eichler, N. Lubenow, U. Strobel, and A. Greinacher Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin Blood, January 15, 2004; 103(2): 613 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Koster and T. Fischer Management of Patients with Heparin-Induced Thrombocytopenia During Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2003; 7(4): 411 - 416. [Abstract] [PDF]
|
|
|
|
|
|
A. Greinacher, N. Lubenow, and P. Eichler Anaphylactic and Anaphylactoid Reactions Associated With Lepirudin in Patients With Heparin-Induced Thrombocytopenia Circulation, October 28, 2003; 108(17): 2062 - 2065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Greinacher, P. Eichler, D. Albrecht, U. Strobel, B. Potzsch, and B. I. Eriksson Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance Blood, April 1, 2003; 101(7): 2617 - 2619. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Alving, C. W. Francis, W. R. Hiatt, and M. R. Jackson Consultations on Patients with Venous or Arterial Diseases Hematology, January 1, 2003; 2003(1): 540 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. G. DeLoughery Thrombocytopenia in Critical Care Patients J Intensive Care Med, November 1, 2002; 17(6): 267 - 282. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Fenyvesi, I. Joerg, and J. Harenberg Influence of Lepirudin, Argatroban, and Melagatran on Prothrombin Time and Additional Effect of Oral Anticoagulation Clin. Chem., October 1, 2002; 48(10): 1791 - 1794. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Mureebe and D. Silver Heparin-Induced Thrombocytopenia: Pathophysiology and Management Vascular and Endovascular Surgery, May 1, 2002; 36(3): 163 - 170. [Abstract] [PDF]
|
|
|
|
|
|
E. Muhl, H.-J. Siemens, P. Kujath, and H.-P. Bruch Therapy and Monitoring of Heparin-Induced Thrombocytopenia Type II in Critically Ill Patients During Continuous Venovenous Hemodiafiltration: Comparison of aPTT and Ecarin Clotting Time for Monitoring of r-Hirudin Therapy J Intensive Care Med, January 1, 2002; 17(1): 34 - 40. [Abstract] [PDF]
|
|
|
|
|
|
B. E. Lewis, D. E. Wallis, S. D. Berkowitz, W. H. Matthai, J. Fareed, J. M. Walenga, J. Bartholomew, R. Sham, R. G. Lerner, Z. R. Zeigler, et al. Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia Circulation, April 10, 2001; 103(14): 1838 - 1843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Greinacher and N. Lubenow Recombinant Hirudin in Clinical Practice : Focus on Lepirudin Circulation, March 13, 2001; 103(10): 1479 - 1484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Eikelboom, S. S. Anand, S. R. Mehta, J. I. Weitz, C. Yi, and S. Yusuf Prognostic Significance of Thrombocytopenia During Hirudin and Heparin Therapy in Acute Coronary Syndrome Without ST Elevation : Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) Study Circulation, February 6, 2001; 103(5): 643 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hirsh, T. E. Warkentin, S. G. Shaughnessy, S. S. Anand, J. L. Halperin, R. Raschke, C. Granger, E. M. Ohman, and J. E. Dalen Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety Chest, January 1, 2001; 119(1_suppl): 64S - 94S. [Full Text] [PDF]
|
|
|
|
|
|
P. Eichler, H.-J. Friesen, N. Lubenow, B. Jaeger, and A. Greinacher Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance Blood, October 1, 2000; 96(7): 2373 - 2378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Gordon and J. A Beckman Successful anticoagulation with hirudin in a patient with mesenteric venous thrombosis and multiple coagulation abnormalities Vascular Medicine, August 1, 2000; 5(3): 159 - 162. [Abstract] [PDF]
|
|